LifeStance Health Group (LFST) Projected to Post Quarterly Earnings on Thursday

Key Points

• LifeStance Health Group is expected to report Q3 2026 results on November 5, with analysts forecasting earnings of $0.0369 per share and revenue of $431.59 million.
• The company exceeded estimates in its latest quarter, reporting $0.06 EPS and $435.35 million in revenue, up 26.1% year over year.
• LFST shares have surged near their 12-month high, while analyst sentiment remains a “Moderate Buy” with an average price target of $13.12; insiders have sold more than $146 million of stock in the past three months.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect LifeStance Health Group to announce earnings of $0.0369 per share and revenue of $431.59 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company had revenue of $435.35 million for the quarter, compared to analysts' expectations of $414.58 million. During the same period last year, the firm posted ($0.01) earnings per share. The business's quarterly revenue was up 26.1% compared to the same quarter last year. On average, analysts expect LifeStance Health Group to post $0.16 EPS for the current fiscal year and $0.23 EPS for the next fiscal year.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $13.39 on Thursday. LifeStance Health Group has a 12-month low of $4.77 and a 12-month high of $13.63. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 103.01 and a beta of 1.24. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The firm has a fifty day moving average of $12.45 and a 200-day moving average of $9.28.

Insiders Place Their Bets

In other news, COO Lisa Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at $3,051,985.65. This represents a 14.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the transaction, the insider owned 98,101,407 shares of the company's stock, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,777,580 shares of company stock valued at $146,433,781 in the last three months. 3.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LFST has been the topic of several research analyst reports. Weiss Ratings upgraded LifeStance Health Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 11th. Zacks Research cut LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. JPMorgan Chase & Co. increased their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 14th. Canaccord Genuity Group increased their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. Finally, KeyCorp raised their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $13.12.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.